Predicting difference in mean survival time from cause-specific hazard ratios for women diagnosed with breast cancer
- 19 January 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 31 (3), 597-601
- https://doi.org/10.1093/eurpub/ckaa252
Abstract
Relative reduction in breast cancer mortality is the preferred outcome measure for evaluation of mammography screening. However, mean survival time has been advocated as a better and more intuitive outcome for risk communication. We have previously introduced a method to predict difference in mean survival time from empirical hazard ratios for all-cause mortality. In this article, we aim to investigate the association between hazard ratios for breast cancer mortality and the difference in mean survival time for women diagnosed with breast cancer. We retrieved data on all women diagnosed with first-time invasive breast cancer in Norway from 1960 through 2004. Women were followed until emigration or end of follow-up on 31 December 2015, whichever came first. Observed differences in mean survival times and hazard ratios for both breast cancer death and death from causes other than breast cancer were obtained for neighbouring time periods defined by women’s age and year of diagnosis. Based on previously developed methods, we fitted a linear relationship between observed differences in mean survival and logarithmic hazard ratios. A linear association was found between breast cancer-specific hazard ratios and difference in mean survival time for women diagnosed with breast cancer. This association was also estimated with adjustment for other causes of death than breast cancer. The change in mean survival time could be predicted from an estimated reduction in breast cancer mortality. This outcome measure can contribute to better and more understandable risk information about the effect of mammography screening programmes.This publication has 15 references indexed in Scilit:
- Decisions on statin therapy by patients’ opinions about survival gains: cross sectional survey of general practitionersBMC Family Practice, 2015
- It Is Time to Initiate Another Breast Cancer Screening TrialAnnals of Internal Medicine, 2014
- When the entire population is the sample: strengths and limitations in register-based epidemiologyEuropean Journal of Epidemiology, 2014
- Screening for breast cancer with mammographyEmergencias, 2013
- The benefits and harms of breast cancer screening: an independent reviewThe Lancet, 2012
- Modeling the impact of population screening on breast cancer mortality in the United StatesThe Breast, 2011
- Data quality at the Cancer Registry of Norway: An overview of comparability, completeness, validity and timelinessEuropean Journal of Cancer, 2009
- Helping Doctors and Patients Make Sense of Health StatisticsPsychological Science in the Public Interest, 2007
- Long-term effects of mammography screening: updated overview of the Swedish randomised trialsThe Lancet, 2002
- A Heteroskedasticity-Consistent Covariance Matrix Estimator and a Direct Test for HeteroskedasticityEconometrica, 1980